Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAcuity RM Group plc Regulatory News (ACRM)

Share Price Information for Acuity RM Group plc (ACRM)

Share Price is delayed by 15 minutes
Get Live Data
0.75    -0.175 (-18.92%)
Bid:
0.70
Ask:
0.80
Spread: 0.10 (14.286%)
Market Cap: £1.83m
ACRM Live PriceLast checked at - London Stock Exchange

Intraday Acuity RM Group plc Share Chart

Changes in share options

7 Feb 2025 07:00

Acuity RM Group Plc - Changes in share options

Acuity RM Group Plc - Changes in share options

PR Newswire

LONDON, United Kingdom, February 07

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

7 February 2025

 

Acuity RM Group plc

("Acuity" or the "Company")

Changes in Share Options

Acuity (AIM:ACRM), the software group, announces that, when Kerry Chambers left the Company her options lapsed. On 6 February 2025, share options were granted to David Rajakovich, the new Chief Executive. These options are identical in all respects to the lapsed options save as to date of grant and expiry date as detailed below: 

 

Name

Position

Options granted

Total number of options held

David Rajakovich

Chief Executive

2,251,922

2,251,922

 

The options have been granted under the Company's approved Enterprise Management Incentive share option scheme (the "EMI Scheme") and have an exercise price of 3.75 pence per share, the closing mid-market price of the shares, as derived from the AIM Appendix to the London Stock Exchange Daily Official List for 25 June 2024, (being the then market price as defined under the rules of the EMI Scheme), which compares with 6 February 2025 closing mid-market price of 1.85 pence per share.  The options are exercisable in whole or in part at any time in the next five years conditional on the market price (under the rules of the EMI Scheme) of the Company's shares reaching double the exercise price for a period of at least five consecutive trading days.

  

The total number of options granted and outstanding under the EMI Scheme is 7,131,088, representing approximately 4.75 per cent of the Company's current issued share capital. In addition, there are 1,600,000 unapproved share options. Accordingly, the total number of options that are outstanding is 8,731,088, representing approximately 5.82 per cent of the current issued share capital.

Enquiries:

For further information: 

Acuity RM Group plc

020 3582 0566

Angus Forrest, Chairman

https://www.acuityrmgroup.com

 

Zeus (NOMAD & Joint Broker)

https://www.zeuscapital.co.uk

Mike Coe / James Bavister

020 3829 5000

 

Peterhouse Capital Limited (Joint Broker)

020 7469 0936

Lucy Williams / Duncan Vasey

 

Clear Capital Markets Limited (Joint Broker)Bob Roberts

020 3869 6080

 

Note to Editors

Acuity RM Group plc

Acuity RM Group plc (AIM: ACRM), is an established provider of risk management services. Its award-winning software platform, STREAM®, which collects and analyses data about organisations to improve business decisions and management, is currently used by around 70 organisations in markets including government, utilities, defence, broadcasting, manufacturing and healthcare.

The Company is focused on delivering long term, sustainable growth in shareholder value from organic growth and complementary acquisitions.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Rajakovich

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Acuity RM Group plc

b)

 

LEI

 

 

213800JHJFKALDJA5X97 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Share Options over Ordinary shares of 0.1p each

 

 

GB00BR0WHY71 

b)

 

Nature of the transaction

 

 

Grant of Options

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

3.75p

2,251,922

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

 n/a

 

 

 

e)

 

Date of the transaction

 

6 February 2025

f)

 

Place of the transaction

 

Outside of a trading venue

 

 



12
Date   Source Headline
17th Jun 20267:00 amPRNRetail Offer
16th Jun 20264:33 pmRNSFundraise of approximately £400,000
8th Jun 20267:00 amRNS-RContract Expansion
24th Apr 20267:00 amPRNTrading Statement
23rd Apr 20267:00 amPRNTrading Statement
27th Mar 20267:00 amPRNIssue of Equity
16th Mar 20267:00 amRNSProduct Launch
16th Mar 20267:00 amPRNProduct Launch
9th Mar 20267:00 amRNS-RA client’s experience of Acuity
24th Feb 20267:00 amRNS-RContract win
17th Feb 20267:00 amPRNContract
5th Feb 20262:35 pmPRNDirector/PDMR Shareholding
5th Feb 20261:17 pmPRNPDMR Shareholding
4th Feb 20267:00 amPRNHolding in Company
2nd Feb 20267:00 amPRNContract
15th Jan 20268:07 pmPRNHoldings in Company and Director Dealing
15th Jan 20267:00 amPRNStatement re Investor Presentation 10.00am 21 January
13th Jan 20267:00 amPRNTrading Statement
18th Nov 20258:47 amRNSHolding(s) in Company
17th Nov 20257:00 amPRNStatement re sale of investment
13th Nov 20254:06 pmPRNHolding(s) in Company
12th Nov 20257:00 amPRNDirectorate changes
21st Oct 20257:00 amRNS-RContract Win
7th Oct 20257:00 amPRNContract
22nd Sep 20257:00 amPRNIssue of Equity
16th Sep 20251:03 pmPRNHolding(s) in Company
5th Sep 20257:00 amPRNStatement re Investor presentation 10.00am 11 September
2nd Sep 20257:00 amPRNHalf-year Report
18th Aug 20257:00 amRNS-RFirst customer win for new product
30th Jul 20251:52 pmPRNResult of AGM
29th Jul 20257:00 amPRNIssue of Equity
11th Jul 202511:33 amPRNHolding(s) in Company
7th Jul 20254:09 pmPRNAnnual Report and Notice of AGM
7th Jul 202512:23 pmPRNHolding(s) in Company
7th Jul 20257:00 amPRNProduct Launch
4th Jul 202511:56 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNStatement re Final Results
30th Jun 20251:54 pmPRNIssue of Equity
26th Jun 20256:04 pmPRNHolding(s) in Company
25th Jun 20259:30 amRNSFinal Results
19th Jun 20253:22 pmPRNHolding(s) in Company
13th Jun 202510:30 amPRNStatement re Business and Directorate
21st May 20257:00 amPRNIssue of Equity
19th May 20259:45 amPRNIssue of Equity
19th May 20257:00 amPRNIssue of Equity
6th Mar 20257:00 amPRNStatement re Investor Presentation
17th Feb 20257:00 amPRNDirector/PDMR Shareholding
7th Feb 20257:00 amPRNChanges in share options
5th Feb 20258:59 amPRNCorrection to Year end Update
4th Feb 20257:00 amPRNTrading Statement
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.